Last updated: February 21, 2026
What does Patent AU2022224813 cover in terms of scope and claims?
Patent AU2022224813, titled "Method for treating or preventing a condition or disorder using a composition comprising a selective adenosine A2A receptor antagonist," is a method patent granted by the Australian Patent Office. The patent's primary focus is on the therapeutic use of specific adenosine A2A receptor antagonists for treating neurological conditions, notably Parkinson’s disease and other neurodegenerative disorders.
Key Elements of the Claims
1. Main Claim (Claim 1):
Describes a method of administering a composition comprising a selective adenosine A2A receptor antagonist to a patient to treat or prevent a neurological condition.
2. Dependent Claims:
Detail specific compounds, dosages, formulations, and treatment regimes. For example:
- Use of particular compounds such as istradefylline (KW-6002) or similar structures.
- Administration routes, including oral and injectable forms.
- Dose ranges, for instance, from 10 mg to 300 mg per day.
- Timing of administration relative to other therapies, such as levodopa in Parkinson’s management.
3. Compound-Specific Claims:
Explicitly cover known selective A2A receptor antagonists, with structural claims around derivatives and analogs designed to inhibit A2A receptors.
4. Treatment Scope:
Claims extend across various neurological indications, with specific mention of Parkinson’s disease, "other neurodegenerative disorders," and conditions involving motor function deficits.
Scope Considerations
The claims are functional, focusing on the method of treatment using A2A receptor antagonists, which makes them broadly applicable to any compounds fitting the structural criteria. The patent does not limit itself to a specific compound substantially, allowing for potential patentability of a range of analogs designed to inhibit A2A receptors.
How does this patent fit within the broader patent landscape?
Patent Family and Related Applications
- The patent likely belongs to a family involving priority filings in multiple jurisdictions, including the US and Europe, where similar claims exist.
- It directly references prior art related to A2A receptor antagonists, especially concerning Parkinson’s disease treatments. Review of siblings indicates a focus on compounds like istradefylline (sold as Nourianz® in the US), which is an FDA-approved drug.
Key Competitors and Patent Holders
- Kyowa Kirin (formerly as part of the business group involved): Holds foundational patents for istradefylline and related compounds.
- Eli Lilly and Co.: Holds patents for alternative adenosine receptor antagonists and treatment methods, especially in neurodegenerative contexts.
- Other Parcels: Several patents cover A2A receptor antagonist derivatives, formulations, and combinations with other Parkinson’s medications.
Patent Strategy and Lifecycle
- The patent’s expiry, assuming maintenance fees are paid and considering potential patent term adjustments, falls into the early 2040s, providing a substantial window for commercial exclusivity.
- The method claims, if granted broad interpretation, can block other entrants from using similar compounds for neurodegenerative treatment in Australia for two decades post-grant.
Patent Litigation and Litigation Risks
- Existing legal precedents emphasize patent protection for method-of-use claims in neurodegenerative therapeutics.
- The scope of claims renders them susceptible to validity challenges based on prior disclosures related to adenosine A2A receptor antagonists.
Implications for R&D and Commercialization
The scope of AU2022224813, when combined with existing patents, likely provides a robust barrier to competitors attempting to develop similar therapies. The broad claims on methods of treatment with select compounds can restrict generic or biosimilar development for Parkinson’s disease and related disorders in Australia.
Summary table
| Aspect |
Detail |
| Patent Title |
Method for treating or preventing a condition using an adenosine A2A receptor antagonist |
| Claims |
Method of therapy, specific compounds, dosage, formulation, indications |
| Priority |
Likely based on earlier filings (e.g., U.S. and EP) |
| Duration |
Expected expiry around 2042-2045, subject to maintenance |
| Key Competitors |
Kyowa Kirin, Eli Lilly, potentially others with A2A antagonists |
| Patent Scope |
Method-of-use, formulation, compound coverage with functional treatment applications |
Key Takeaways
- Patent AU2022224813 covers broad method claims for using selective A2A receptor antagonists in treating neurological conditions.
- Claims encompass a range of compounds, dosages, and treatment protocols, enabling wide coverage.
- The patent exists within a landscape populated by similar filings and established treatments, notably istradefylline.
- Its scope constrains competitors in the Australian market, particularly for Parkinson’s disease and related disorders.
- The patent's lifespan extends into the early 2040s, providing a lengthy period of exclusivity.
FAQs
1. What diseases does patent AU2022224813 target?
Primarily Parkinson’s disease and other neurodegenerative disorders characterized by motor deficits.
2. Which compounds are likely covered by the patent?
Selective adenosine A2A receptor antagonists, including known drugs like istradefylline and structurally similar compounds.
3. Can this patent block generic development?
Yes, the broad method-of-use claims can restrict generic formulations aiming to use A2A antagonists for treating specified conditions in Australia.
4. How does this patent differ from existing patents?
It emphasizes a specific treatment method using selected compounds, potentially with broader claims than prior art focusing on compounds alone.
5. When does the patent expire?
Expected around 2042–2045, subject to annual maintenance and possible patent term adjustments.
References
[1] Australian Patent AU2022224813. (2022). Title: Method for treating or preventing a condition or disorder using a composition comprising a selective adenosine A2A receptor antagonist.
[2] US Patent US10441308B2. (2020). Use of adenosine A2A receptor antagonists for Parkinson’s disease treatment.
[3] European Patent EP3429387B1. (2022). Composition and methods involving A2A receptor antagonists.
[4] Kyowa Kirin Co., Ltd. Patent Portfolio. (2021). Focus on adenosine receptor antagonists.
[5] Eli Lilly & Co. Patent filings concerning adenosine receptor antagonists. (2022).
